CY1121596T1 - Αμιδια βενζοξαζινονης ως αλατοκορτικοειδεις ρυθμιστες υποδοχεα - Google Patents
Αμιδια βενζοξαζινονης ως αλατοκορτικοειδεις ρυθμιστες υποδοχεαInfo
- Publication number
- CY1121596T1 CY1121596T1 CY20191100097T CY191100097T CY1121596T1 CY 1121596 T1 CY1121596 T1 CY 1121596T1 CY 20191100097 T CY20191100097 T CY 20191100097T CY 191100097 T CY191100097 T CY 191100097T CY 1121596 T1 CY1121596 T1 CY 1121596T1
- Authority
- CY
- Cyprus
- Prior art keywords
- benzoxazinone
- amids
- salt
- formula
- endothelial
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
- C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Αποκαλύπτονται ορισμένα παράγωγα αμιδίων βενζοξαζινόνης χημικού τύπου (I), ή φαρμακευτικά αποδεκτά άλατα αυτών, (Χημικού Τύπου (I)) που δρουν ως αλατοκορτικοειδείς (MR) ρυθμιστές υποδοχέα που μπορούν μειώσουν το οξειδωτικό στρες στο ενδοθήλιο και συνεπώς βελτιώνουν την αγγειακή λειτουργία, με μεθόδους για τη πιθανή θεραπευτική χρήση τους, με φαρμακευτικές συνθέσεις που τα περιέχουν και με διεργασίες για την προετοιμασία τέτοιων ενώσεων.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462018790P | 2014-06-30 | 2014-06-30 | |
PCT/GB2015/051860 WO2016001631A1 (en) | 2014-06-30 | 2015-06-26 | Benzoxazinone amides as mineralocorticoid receptor modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1121596T1 true CY1121596T1 (el) | 2020-05-29 |
Family
ID=53539739
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20191100097T CY1121596T1 (el) | 2014-06-30 | 2019-01-24 | Αμιδια βενζοξαζινονης ως αλατοκορτικοειδεις ρυθμιστες υποδοχεα |
Country Status (25)
Country | Link |
---|---|
US (2) | US10017502B2 (el) |
EP (1) | EP3160948B1 (el) |
JP (1) | JP6368383B2 (el) |
KR (1) | KR102012222B1 (el) |
CN (1) | CN106536491B (el) |
AR (1) | AR101036A1 (el) |
AU (1) | AU2015282450C1 (el) |
CA (1) | CA2953655C (el) |
CY (1) | CY1121596T1 (el) |
DK (1) | DK3160948T3 (el) |
EA (1) | EA029518B1 (el) |
ES (1) | ES2707726T3 (el) |
HR (1) | HRP20190147T1 (el) |
HU (1) | HUE042370T2 (el) |
LT (1) | LT3160948T (el) |
ME (1) | ME03316B (el) |
MX (1) | MX367404B (el) |
PL (1) | PL3160948T3 (el) |
PT (1) | PT3160948T (el) |
RS (1) | RS58274B1 (el) |
SI (1) | SI3160948T1 (el) |
TR (1) | TR201900659T4 (el) |
TW (1) | TWI677498B (el) |
UY (1) | UY36195A (el) |
WO (1) | WO2016001631A1 (el) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106536491B (zh) * | 2014-06-30 | 2018-12-18 | 阿斯利康(瑞典)有限公司 | 作为盐皮质激素受体调节剂的苯并噁嗪酮酰胺 |
WO2020016335A1 (en) | 2018-07-19 | 2020-01-23 | Astrazeneca Ab | Methods of treating hfpef employing dapagliflozin and compositions comprising the same |
CN112107568B (zh) * | 2019-06-19 | 2022-03-25 | 北京龙嘉博创医药科技有限公司 | 二芳基酰胺类化合物及其应用 |
JP2022530575A (ja) * | 2019-08-30 | 2022-06-30 | アストラゼネカ・アクチエボラーグ | ダパグリフロジンを用いて、駆出率が低下した心不全を治療する方法 |
TW202220672A (zh) | 2020-07-27 | 2022-06-01 | 瑞典商阿斯特捷利康公司 | 用達格列淨治療慢性腎臟病之方法 |
WO2022262736A1 (zh) | 2021-06-15 | 2022-12-22 | 正大天晴药业集团股份有限公司 | 苯并恶嗪酮类衍生物 |
WO2024015425A1 (en) | 2022-07-14 | 2024-01-18 | Fmc Corporation | Herbicidal benzoxazines |
WO2024047574A1 (en) | 2022-09-01 | 2024-03-07 | Astrazeneca Ab | Combination of sglt2 inhibitors and mineralcorticoid receptor modulators for use in treatment of cardiorenal diseases |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1385835A1 (en) * | 2001-04-23 | 2004-02-04 | Astrazeneca AB | Benzoxazinone derivatives for use in the treatment of angiogenesis |
WO2004056820A1 (en) * | 2002-12-20 | 2004-07-08 | Warner-Lambert Company Llc | Benzoxazines and derivatives thereof as inhibitors of pi3ks |
MX2007000449A (es) * | 2004-07-14 | 2007-03-28 | Ligand Pharm Inc | Compuestos moduladores de receptor intracelular y metodos. |
RU2007107177A (ru) * | 2004-07-28 | 2008-09-10 | Айрм Ллк (Bm) | Соединения и композиции, как модуляторы ядерных рецепторов стероидных гормонов |
US20090253687A1 (en) | 2005-12-28 | 2009-10-08 | Shoji Fukumoto | Fused Heterocyclic Compounds and Their Use as Mineralocorticoid Receptor Ligands |
TWI385161B (zh) | 2006-02-02 | 2013-02-11 | Mitsubishi Tanabe Pharma Corp | 含氮雜雙環化合物 |
PL2089367T3 (pl) | 2006-10-31 | 2012-04-30 | Pfizer Prod Inc | Związki pirazolinowe jako antagoniści receptora mineralokortykoidowego |
DE102007009494A1 (de) | 2007-02-27 | 2008-08-28 | Bayer Healthcare Ag | Substituierte 4-Aryl-1, 4-dihydro-1,6-naphthyridinamide und ihre Verwendung |
US8063090B2 (en) | 2007-03-23 | 2011-11-22 | Merck Sharp & Dohme Corp. | Mineralocorticoid receptor modulators |
CN101679243B (zh) | 2007-04-09 | 2012-09-26 | 第一三共株式会社 | 吡咯衍生物的阻转异构体 |
US8258131B2 (en) | 2007-08-01 | 2012-09-04 | Mitsubishi Tanabe Pharma Corporation | Fused bicyclic compound |
JP5173653B2 (ja) * | 2007-08-01 | 2013-04-03 | 田辺三菱製薬株式会社 | 医薬組成物 |
TWI431010B (zh) | 2007-12-19 | 2014-03-21 | Lilly Co Eli | 礦皮質素受體拮抗劑及使用方法 |
UY31905A (es) * | 2008-06-18 | 2010-01-29 | Astrazeneca Ab | Derivados de benzoxazinona, procesos de preparación, composiciones farmacéuticas conteniéndolos y aplicaciones. |
US20100094000A1 (en) | 2008-09-03 | 2010-04-15 | Takeda Pharmaceutical Company Limited | Pyrazole compounds |
WO2010098286A1 (ja) | 2009-02-25 | 2010-09-02 | 第一三共株式会社 | ミネラルコルチコイド受容体拮抗薬を含有する医薬 |
JP5570536B2 (ja) | 2009-03-12 | 2014-08-13 | イーライ リリー アンド カンパニー | 鉱質コルチコイド受容体アンタゴニストおよび使用方法 |
US20120022058A1 (en) | 2009-04-10 | 2012-01-26 | Pfizer Inc. | 4,5-dihydro-1h-pyrazole compounds and their pharmaceutical uses |
JP2013528598A (ja) | 2010-05-11 | 2013-07-11 | ファイザー・インク | ミネラルコルチコイド受容体拮抗薬としてのモルホリン化合物 |
WO2011141846A2 (en) | 2010-05-11 | 2011-11-17 | Koninklijke Philips Electronics N.V. | Lighting module |
EP2594554A4 (en) | 2010-07-13 | 2014-01-15 | Dainippon Sumitomo Pharma Co | BIARYLAMID DERIVATIVES BZW. PHARMACEUTICALLY PERMITTED SALT FROM THIS |
WO2012064631A1 (en) | 2010-11-10 | 2012-05-18 | Boehringer Ingelheim International Gmbh | Pyridyl ureas as mineralocorticoid receptor antagonists |
CN106536491B (zh) * | 2014-06-30 | 2018-12-18 | 阿斯利康(瑞典)有限公司 | 作为盐皮质激素受体调节剂的苯并噁嗪酮酰胺 |
-
2015
- 2015-06-26 CN CN201580035032.8A patent/CN106536491B/zh active Active
- 2015-06-26 TR TR2019/00659T patent/TR201900659T4/tr unknown
- 2015-06-26 CA CA2953655A patent/CA2953655C/en active Active
- 2015-06-26 SI SI201530572T patent/SI3160948T1/sl unknown
- 2015-06-26 RS RS20190085A patent/RS58274B1/sr unknown
- 2015-06-26 ME MEP-2019-19A patent/ME03316B/me unknown
- 2015-06-26 DK DK15736015.7T patent/DK3160948T3/en active
- 2015-06-26 MX MX2017000183A patent/MX367404B/es active IP Right Grant
- 2015-06-26 ES ES15736015T patent/ES2707726T3/es active Active
- 2015-06-26 US US15/320,379 patent/US10017502B2/en active Active
- 2015-06-26 EA EA201790046A patent/EA029518B1/ru not_active IP Right Cessation
- 2015-06-26 PL PL15736015T patent/PL3160948T3/pl unknown
- 2015-06-26 KR KR1020177002518A patent/KR102012222B1/ko active IP Right Grant
- 2015-06-26 LT LTEP15736015.7T patent/LT3160948T/lt unknown
- 2015-06-26 WO PCT/GB2015/051860 patent/WO2016001631A1/en active Application Filing
- 2015-06-26 UY UY0001036195A patent/UY36195A/es not_active Application Discontinuation
- 2015-06-26 AU AU2015282450A patent/AU2015282450C1/en active Active
- 2015-06-26 PT PT15736015T patent/PT3160948T/pt unknown
- 2015-06-26 EP EP15736015.7A patent/EP3160948B1/en active Active
- 2015-06-26 HU HUE15736015A patent/HUE042370T2/hu unknown
- 2015-06-26 JP JP2016575499A patent/JP6368383B2/ja active Active
- 2015-06-29 US US14/753,239 patent/US9394291B2/en active Active
- 2015-06-29 TW TW104120998A patent/TWI677498B/zh active
- 2015-06-30 AR ARP150102098A patent/AR101036A1/es active IP Right Grant
-
2019
- 2019-01-22 HR HRP20190147TT patent/HRP20190147T1/hr unknown
- 2019-01-24 CY CY20191100097T patent/CY1121596T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1121596T1 (el) | Αμιδια βενζοξαζινονης ως αλατοκορτικοειδεις ρυθμιστες υποδοχεα | |
CY1122966T1 (el) | 5-βρωμο-2,6-δι-(1η-πυραζολ-1-υλ)πυριμιδιν-4-αμινη για χρηση στη θεραπευτικη αγωγη καρκινου | |
CY1121418T1 (el) | Παρεμποδιστες ιου ηπατιτιδας c | |
CY1124548T1 (el) | Παραγωγα μονο- ή δισυποκατεστημενης ινδολης ως αναστολεις αναδιπλασιασμου του δαγκειου ιου | |
CL2017001061A1 (es) | Cromanos sustituidos y métodos para su uso | |
BR112018005497A2 (pt) | compostos heterocíclicos e usos dos mesmos | |
EA201791256A1 (ru) | Производные хиназолина, применяемые для лечения вич | |
CY1120340T1 (el) | Gpr40 ρυθμιστες πυρρολιδινης για τη θεραπεια ασθενειων οπως διαβητη | |
CY1121746T1 (el) | Αναστολεις mgat2 τετραζολονο-υποκατεστημενης διυδροπυριδινονης | |
EA201791304A1 (ru) | Производные изохинолина для лечения вич | |
CY1124059T1 (el) | Αζαβενζιμιδαζολια και χρηση αυτων ως ρυθμιστες υποδοχεα ampa | |
CY1124251T1 (el) | Παραγωγα καρβοξαμιδιου | |
CY1122077T1 (el) | Νεα δακτυλιωμενα φαινοξυακεταμιδια | |
CY1123576T1 (el) | Συμπυκνωμενα παραγωγα θειοφαινιου χρησιμα ως αναστολεις του napi-iib | |
EA201791600A1 (ru) | Производные гидроксиалкилпиперазина в качестве модуляторов cxcr3 рецептора | |
CY1122321T1 (el) | Παραγωγα φθοροϊνδολιου ως θετικοι αλλοστερικοι διαμορφωτες του μουσκαρινικου υποδοχεα μ1 | |
CY1122381T1 (el) | Παραγωγα ιμιδαζοπυριδαζινης ως αναστολεις pi3kbhta | |
EA201692298A1 (ru) | Производные карбоксамидов | |
EA201791480A1 (ru) | Новые производные бензимидазола в качестве антигистаминных агентов | |
NI201600091A (es) | UREAS ASIMÉTRICAS p-SUSTITUIDAS Y USOS MÉDICOS DE LAS MISMAS | |
CY1123185T1 (el) | Παραγωγα ινδολιου | |
MX2016014118A (es) | Moduladores de receptor de proteina g 40 (gpr40) de pirrolidina para tratamiento de enfermedades tales como diabetes. | |
EA201990723A1 (ru) | Кристаллические формы | |
CY1118920T1 (el) | Ενωσεις πιπεραζινης- πιπεριδινης ως αναστολεις του ιου ηπατιτιδας c | |
EA201891680A1 (ru) | Производные индана в качестве модуляторов mglur7 |